Detalhe da pesquisa
1.
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach.
Qual Life Res
; 33(4): 1075-1084, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38265747
2.
Improving access to quality medicines in East Africa: An independent perspective on the East African Community Medicines Regulatory Harmonization initiative.
PLoS Med
; 17(8): e1003092, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785224
3.
EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
Oncologist
; 25(10): 894-902, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32339368
4.
The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Oncologist
; 25(2): e321-e327, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043764
5.
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Oncologist
; 23(5): 631-636, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29192015
6.
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Oncologist
; 23(5): 594-602, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29371479
7.
Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
AAPS PharmSciTech
; 19(2): 489-511, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29027130
8.
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Oncologist
; 22(11): 1339-1346, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28935772
9.
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Oncologist
; 21(1): 102-9, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26621039
10.
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Oncologist
; 21(6): 692-700, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091416
11.
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Oncologist
; 20(3): 329-34, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25673103
12.
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
Oncologist
; 20(2): 196-201, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25616431
13.
The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
Oncologist
; 19(4): 421-5, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24668331
14.
The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Oncologist
; 19(7): 766-73, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24928613
15.
Regulatory Reply to the ATMOSPHERE Data Monitoring Committee.
N Engl J Med
; 374(16): 1585-6, 2016 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27043362
16.
The evolving value assessment of cancer therapies: Results from a modified Delphi study.
Health Policy Open
; 6: 100116, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38464704
17.
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
Oncologist
; 18(5): 625-33, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23615696
18.
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Oncologist
; 23(7): 870, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30037941
19.
The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.
Oncologist
; 18(9): 1032-42, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23966222
20.
How can a joint European health technology assessment provide an 'additional benefit' over the current standard of national assessments? : Insights generated from a multi-stakeholder survey in hematology/oncology.
Health Econ Rev
; 12(1): 30, 2022 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35652987